Novo Nordisk A/S (BVMF:N1VO34)

Market Cap	958.10B -40.4%
Revenue (ttm)	263.81B +8.1%
Net Income	98.15B +16.6%
EPS	22.06 +16.8%
Shares Out	n/a
PE Ratio	9.76
Forward PE	13.25
Dividend	0.77 (2.80%)
Ex-Dividend Date	Mar 27, 2026

Volume	60,140
Open	26.64
Previous Close	27.59
Day's Range	26.55 - 27.30
52-Week Range	22.90 - 57.25
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 67,900
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: N1VO34

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK